

Stina Syvnen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6317724/stina-syvanen-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

1,803
citations

23
h-index

42
g-index

61
ext. papers

2,234
ext. citations

5.6
avg, IF

4.93
L-index

#	Paper	IF	Citations
57	In vivo imaging of alpha-synuclein with antibody-based PET.. <i>Neuropharmacology</i> , 2022 , 208, 108985	5.5	1
56	Passive and receptor mediated brain delivery of an anti-GFAP nanobody.. <i>Nuclear Medicine and Biology</i> , 2022 ,	2.1	2
55	Advances in the development of new biomarkers for Alzheimer's disease.. <i>Translational Neurodegeneration</i> , 2022 , 11, 25	10.3	2
54	PET Imaging in Preclinical Anti-ADrug Development.. <i>Pharmaceutical Research</i> , 2022 , 1	4.5	0
53	Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-AβAffibodies.. <i>Pharmaceutical Research</i> , 2022 , 1	4.5	0
52	Principles of PET and Its Role in Understanding Drug Delivery to the Brain. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2022 , 329-352	0.5	
51	In Vivo Studies of Drug BBB Transport: Translational Challenges and the Role of Brain Imaging. <i>Handbook of Experimental Pharmacology</i> , 2021 , 1	3.2	1
50	C-PIB and I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	4
49	Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 2529-2541	5.7	1
48	Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. <i>Fluids and Barriers of the CNS</i> , 2021 , 18, 26	7	9
47	Enhanced neprilysin-mediated degradation of hippocampal Aβ2 with a somatostatin peptide that enters the brain. <i>Theranostics</i> , 2021 , 11, 789-804	12.1	8
46	Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease. <i>Molecular Imaging and Biology</i> , 2021 , 23, 665-675	3.8	9
45	In vivo imaging of synaptic density with [C]UCB-J PET in two mouse models of neurodegenerative disease. <i>NeuroImage</i> , 2021 , 239, 118302	7.9	8
44	Brain Distribution of Drugs: Pharmacokinetic Considerations. <i>Handbook of Experimental Pharmacology</i> , 2020 , 1	3.2	3
43	Blocking of efflux transporters in rats improves translational validation of brain radioligands. <i>EJNMMI Research</i> , 2020 , 10, 124	3.6	5
42	Chemical imaging of evolving amyloid plaque pathology and associated Aβpeptide aggregation in a transgenic mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020 , 152, 602-616	6	8
41	SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-βantibody in a mouse model of Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020 , 9, 37	10.3	18

40	Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid- β in Brain. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 4460-4468	5.7	7
39	Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle. <i>FASEB Journal</i> , 2020 , 34, 13272-13283	0.9	18
38	Long-Term Effects of Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 72, 161-180	4.3	13
37	Engineered antibodies: new possibilities for brain PET?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2848-2858	8.8	27
36	Pyroglutamation of amyloid- β 42 (A β -42) followed by A β -40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <i>Journal of Biological Chemistry</i> , 2019 , 294, 6719-6732	5.4	30
35	High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. <i>NeuroImage</i> , 2019 , 184, 881-888	7.9	25
34	Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease. <i>Molecular Imaging and Biology</i> , 2018 , 20, 605-614	3.8	31
33	Efficient clearance of A β protofibrils in APP-transgenic mice treated with a brain-penetrating bifunctional antibody. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 49	9	28
32	Antibody-Based In Vivo PET Imaging Detects Amyloid- β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1885-1891	8.9	23
31	Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology. <i>Neuropharmacology</i> , 2018 , 128, 482-491	5.5	23
30	Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2018 , 3, 11	5.8	4
29	Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy. <i>Neuropharmacology</i> , 2018 , 143, 1-9	5.5	21
28	A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging. <i>NeuroImage</i> , 2017 , 148, 55-63	7.9	28
27	Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations. <i>NeuroImage</i> , 2017 , 155, 177-186	7.9	20
26	Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [C]ABP688 PET imaging and ex vivo immunoblotting. <i>Neuropharmacology</i> , 2017 , 113, 293-300	5.5	21
25	Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 347-355	5.7	46
24	Cationization increases brain distribution of an amyloid-beta protofibril selective F(ab) γ fragment. <i>Biochemical and Biophysical Research Communications</i> , 2017 , 493, 120-125	3.4	17
23	Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid- β . <i>Scientific Reports</i> , 2017 , 7, 17254	4.9	23

22	Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. <i>Biological Procedures Online</i> , 2017 , 19, 11	8.3	31
21	Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor. <i>Theranostics</i> , 2017 , 7, 308-318	12.1	79
20	Probing amyloid- β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry. <i>Journal of Neurochemistry</i> , 2016 , 138, 469-78	6	26
19	Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease. <i>Nature Communications</i> , 2016 , 7, 10759	17.4	105
18	(R)-[¹¹ C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: evaluation in a rat epilepsy model. <i>Neuropharmacology</i> , 2014 , 85, 104-12	5.5	34
17	[¹¹ C]quinidine and [¹¹ C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 764-75	2.1	20
16	Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. <i>ACS Chemical Neuroscience</i> , 2013 , 4, 225-37	5.7	54
15	Specific uptake of an amyloid- β protofibril-binding antibody-tracer in A β P transgenic mouse brain. <i>Journal of Alzheimer's Disease</i> , 2013 , 37, 29-40	4.3	43
14	Altered GABA _A receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using ¹¹ C-flumazenil and PET. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1974-83	8.9	24
13	Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry—a study in rats subjected to status epilepticus by kainate. <i>AAPS Journal</i> , 2012 , 14, 87-96	3.7	23
12	Synthesis and preclinical evaluation of [¹¹ C]D617, a metabolite of (R)-[¹¹ C]verapamil. <i>Nuclear Medicine and Biology</i> , 2012 , 39, 530-9	2.1	15
11	Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[¹¹ C]verapamil positron emission tomography. <i>EJNMMI Research</i> , 2012 , 2, 58	3.6	15
10	[¹¹ C]phenytoin revisited: synthesis by [¹¹ C]CO carbonylation and first evaluation as a P-gp tracer in rats. <i>EJNMMI Research</i> , 2012 , 2, 36	3.6	28
9	[¹¹ C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein. <i>EJNMMI Research</i> , 2012 , 2, 12	3.6	15
8	Simultaneous in vivo measurements of receptor density and affinity using [¹¹ C]flumazenil and positron emission tomography: comparison of full saturation and steady state methods. <i>NeuroImage</i> , 2011 , 57, 928-37	7.9	7
7	(R)-[¹¹ C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. <i>BMC Medical Imaging</i> , 2011 , 11, 1	2.9	38
6	Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. <i>Current Topics in Medicinal Chemistry</i> , 2010 , 10, 1799-809	3	26
5	Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 635-43	4.3	258

4	On the rate and extent of drug delivery to the brain. <i>Pharmaceutical Research</i> , 2008 , 25, 1737-50	4.5	352
3	Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. <i>Journal of Pharmaceutical Sciences</i> , 2008 , 97, 5386-400	3.9	23
2	Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. <i>NeuroImage</i> , 2006 , 32, 1134-41	7.9	50
1	Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. <i>Pharmaceutical Research</i> , 2006 , 23, 705-17	4.5	53